Allarity Therapeutics Inc... (ALLR)
1.01
-0.06 (-5.61%)
At close: Jan 14, 2025, 3:59 PM
1.02
0.99%
Pre-market Jan 15, 2025, 08:35 AM EST
undefined% (undefined)
| Bid | 1 |
| Market Cap | 4.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 5449.42 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.07 |
| Volume | 690,873 |
| Avg. Volume (20D) | 1,134,390 |
| Open | 1.05 |
| Previous Close | 1.07 |
| Day's Range | 1.00 - 1.07 |
| 52-Week Range | 0.90 - 300.00 |
| Beta | undefined |
About ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microt...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 21, 2021
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ALLR
Website https://www.allarity.com
4 months ago ·
Source
+18.4%
Allarity Therapeutics shares are trading higher. T...
Unlock content with
Pro Subscription
4 months ago ·
Source
+10.85%
Allarity Therapeutics shares are trading lower. The company implemented a 1-for-30 reverse stock split to regain Nasdaq listing compliance.
